Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Electra Therapeutics targets $977.6 million valuation in US IPO

14 September 2026 · By · Wire by Fusion42

Published

14 September 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at kfgo.com →

◆ Verified

Fusion42 · 14 September 2026 · Fusion42 review

Electra Therapeutics aims for a $977.6 million valuation in its US IPO to raise up to $346.7 million, funding clinical trials of its lead drug ipsoprubart and advancing other drug candidates. The biotech company focuses on immunological diseases and cancer therapies, listing on Nasdaq under symbol ETRA.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

A biotech IPO is moving forward despite market volatility, signalling fund flows returning to late-stage immunotherapy firms. If you develop uncommon drug candidates, this window may open capital access for the next 6-12 months.

◆ Coverage

1 source · 14 Sep 2026

◆ Related on Wire

◆ Topics

Biotechipobiotechclinical-trialsfundraisingimmunotherapy